Table 1.
Patient Characteristics, N=39
| Characteristic | No (%) |
|---|---|
| Age, years, median (IQR) | 64.2 (49-69.8) |
| Sex, male* | 32 (82) |
| Race, white† | 35 (89.7) |
| Cancer type | |
| Melanoma | 14 (35.8) |
| Genitourinary | 10 (25.6) |
| Lung/head and neck | 6 (15.3) |
| Gastrointestinal | 7 (17.9) |
| Hematological | 1 (2.5) |
| Renal | 1 (2.4) |
| Type of ICI | |
| Anti-CTLA-4 monotherapy | 2 (5.1) |
| Anti-PD-1/L1 monotherapy | 5 (12.8) |
| Combination anti-CTLA-4 and anti-PD-1/L1 | 32 (82) |
| Duration of follow-up from colitis diagnosis to last follow-up, months, median (IQR) | 14.2 (9.1-41.2) |
Abbreviations: CTLA-4, cytotoxic T lymphocyte antigen 4; ICI, immune checkpoint inhibitor; IQR, interquartile range; PD-1/PD-L1, programmed cell death 1/programmed death ligand 1.
*7 patients (18%) were females.
†3 patients (7.6%) were Hispanic and 1 patient (2.5%) African American.